1887

Abstract

SUMMARY

Two temperature-sensitive () mutants ( 21 and 24), which could complement each other, were isolated from cell culture-passaged murine cytomegalovirus (CC-MCMV). Characterization revealed that 21 lacked pathogenicity for suckling mice, neurovirulence for weanling mice and productive chronic infection in the salivary gland, whereas 24 was positive only for the first two parameters; both mutants retained immunogenicity comparable to that of the wild-type CC-MCMV. The immunogenicity of 21 and 24 was assessed by mortality of the immunized mice after challenge with virulent, salivary gland-passaged MCMV (SG-MCMV) and by replication of the challenge virus in the immunized hosts. The protective immunity conferred by 21 was maintained over a period of 3 months without production of infectious viruses in the salivary gland.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-64-9-1983
1983-09-01
2022-01-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/64/9/JV0640091983.html?itemId=/content/journal/jgv/10.1099/0022-1317-64-9-1983&mimeType=html&fmt=ahah

References

  1. Belshe R. B., Richardson L. S., London W. T., Sly D. L., Camargo E., Prevar D. A., Chanock R. M. 1978; Evaluation of five temperature-sensitive mutants of respiratory syncytial virus in primates. II. Genetic analysis of virus recovered during infection. Journal of Medical Virology 3:101–110
    [Google Scholar]
  2. Cheung K.-S., Lang D. J. 1977; Detection of latent cytomegalovirus in murine salivary and prostate explant cultures and cells. Infection and Immunity 15:568–575
    [Google Scholar]
  3. Chong K. T., Gould J. J., Mims C. A. 1981; Neutralization of different strains of murine cytomegalovirus (MCMV) – effect of in vitro passage. Archives of Virology 69:95–104
    [Google Scholar]
  4. Eizuru Y., Minamishima Y. 1979; Co-variation of pathogenicity and antigenicity in murine cytomegalovirus. Microbiology and Immunology 23:559–564
    [Google Scholar]
  5. Elek S. D., Stern H. 1974; Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet i:1–5
    [Google Scholar]
  6. Ho M., Ashman R. B. 1979; Development in vitro of cytotoxic lymphocytes against murine cytomegalovirus. Australian Journal of Biological and Medical Science 57:425–428
    [Google Scholar]
  7. Howard R. J., Balfour H. H. 1977; Prevention of morbidity and mortality of wild murine cytomegalovirus by vaccination with attenuated cytomegalovirus. Proceedings of the Society for Experimental Biology and Medicine 156:365–368
    [Google Scholar]
  8. Hudson J. B. 1979; The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections. Archives of Virology 62:1–29
    [Google Scholar]
  9. Hudson J. B., Misra V., Mosmann T. R. 1976a; Properties of the multicapsid virions of murine cytomegalovirus. Virology 72:225–234
    [Google Scholar]
  10. Hudson I. B., Misra V., Mosmann T. R. 1976b; Cytomegalovirus infectivity: analysis of the phenomenon of centrifugal enhancement of infectivity. Virology 72:235–243
    [Google Scholar]
  11. Ihara S., Hirai K., Watanabe Y. 1978; Temperature-sensitive mutants of human cytomegalovirus: isolation and partial characterization of DNA-minus mutants. Virology 84:218–221
    [Google Scholar]
  12. Jordan M. C. 1980; Adverse effects of cytomegalovirus vaccination in mice. Journal of Clinical Investigation 65:798–803
    [Google Scholar]
  13. Jordan M. C., Shanley J. D., Stevens J. G. 1977; Immunosuppression reactivates and disseminates latent murine cytomegalovirus. Journal of General Virology 31:419–423
    [Google Scholar]
  14. Lang D. J. 1980; Cytomegalovirus immunization: status, prospects, and problems. Reviews of Infectious Diseases 2:449–458
    [Google Scholar]
  15. Lussier G. 1973; Encephalitis caused by murine cytomegalovirus in newborn and weanling mice. Veterinary Pathology 10:366–374
    [Google Scholar]
  16. Mackenzie J. S. 1975; Virulence of temperature-sensitive mutants of foot-and-mouth disease virus. Archives of Virology 48:1–8
    [Google Scholar]
  17. Makino S. 1977; Measles virus mutants and their implications in basic and applied virology. Annales de Microbiologie 128B:507–515
    [Google Scholar]
  18. Mayo D. R., Armstrong J. A., Ho M. 1977; Reactivation of murine cytomegalovirus by cyclophosphamide. Nature, London 261:721–723
    [Google Scholar]
  19. Minamishima Y. 1977; Immunoprophylaxis of experimental cytomegalovirus infection. Annales de Microbiologie 128B:399–407
    [Google Scholar]
  20. Minamishima Y., Eizuru Y. 1974; Protective immunity in cytomegalovirus infection of mice. Proceedings of the First Intersectional Congress of I AMS 4:50–54
    [Google Scholar]
  21. Minamishima Y., Eizuru Y., Yoshida A., Fukunishi R. 1978a; Murine model for immunoprophylaxis of cytomegalovirus infection. I. Efficacy of immunization. Microbiology and Immunology 22:693–700
    [Google Scholar]
  22. Minamishima Y., Shishime Y., Eizuru Y. 1978b; Neurovirulence of murine cytomegalovirus. Abstrac ts, Fourth International Congress for Virology (The Hague, The Netherlands)
    [Google Scholar]
  23. Ohsaki M., Chiba S., Nakao T. 1970; Studies on the murine cytomegalovirus infection; viral growth and histopathological changes in the central nervous system. Virus 2:11–14 (in Japanese with English summary)
    [Google Scholar]
  24. Olding L. B., Jensen F. C., Oldstone M. B. A. 1975; Pathogenesis of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. Journal oj Experimental Medicine 141:561–572
    [Google Scholar]
  25. Osborn J. E. 1981; Cytomegalovirus: pathogenicity, immunology, and vaccine initiatives. Journal of Infectious Diseases 143:618–630
    [Google Scholar]
  26. Osborn J. E., Walker D. L. 1968; Enhancement of infectivity of murine cytomegalovirus in vitro by centrifugal inoculation. Journal of Virology 2:853–858
    [Google Scholar]
  27. OSborn J. E., Walker D. L. 1970; Virulence and attenuation of murine cytomegalovirus. Injection and Immunity 2:228–236
    [Google Scholar]
  28. Parks W. P., Rapp F. 1975; Prospects for herpesvirus vaccination – safety and efficacy considerations. Progress in Medical Virology 21:188–206
    [Google Scholar]
  29. Plotkin S. A. 1981; Cytomegalovirus vaccines. Journal of Infectious Diseases 144:494–495
    [Google Scholar]
  30. Plotkin S. A., Farquhar J., Hornberger E. 1976; Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. Journal of Infectious Diseases 134:470–475
    [Google Scholar]
  31. Starr S. E., Allison A. C. 1977; Role of T lymphocytes in recovery from murine cytomegalovirus infection. Injection and Immunity 17:458–462
    [Google Scholar]
  32. Takahashi M., Okuno Y., Otsuka T., Osame J., Takamizawa A., Sayada T., Kubo T. 1975; Development of live attenuated varicella vaccine. Biken Journal 18:25–33
    [Google Scholar]
  33. Tolpin M. D., Starr S. E., Arbeter A. M., Plotkin S. A. 1980; Inactivated mouse cytomegalovirus vaccine: preparation, immunogenicity and protective effect. Journal oj Infectious Diseases 142:569–574
    [Google Scholar]
  34. Trousdale M. D., Paque R. E., Nealon T., Gauntt C. J. 1979; Assessment of coxsackievirus B3 ts mutants for induction of myocarditis in a murine model. Infection and Immunity 23:486–495
    [Google Scholar]
  35. Yamanishi K., Rapp F. 1977; Temperature-sensitive mutants of human cytomegalovirus. Journal of Virology 24:416–418
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-64-9-1983
Loading
/content/journal/jgv/10.1099/0022-1317-64-9-1983
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error